A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Budesonide (Primary)
  • Indications IgA nephropathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Calliditas Therapeutics
  • Most Recent Events

    • 14 Apr 2018 Status changed from planning to recruiting.
    • 09 Jan 2017 According to a Pharmalink media release, this trial is expected to begin in 2017.
    • 26 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top